Parkinsonian-pyramidal syndrome

Parkinsonian-pyramidal syndrome (PPS), also known as pallido-pyramidal syndrome or PARK15 in some genetic forms, is a rare neurodegenerative disorder characterized by the combination of parkinsonian features (such as bradykinesia, rigidity, resting tremor, and postural instability) together with pyramidal tract signs (such as spasticity, hyperreflexia, extensor plantar responses, and upper motor neuron weakness). The condition primarily affects the central nervous system, specifically the basal ganglia (particularly the globus pallidus) and the corticospinal (pyramidal) tracts. This dual involvement distinguishes it from typical Parkinson disease and places it within a group of complex neurodegenerative conditions. Parkinsonian-pyramidal syndrome is genetically heterogeneous. Several genes have been implicated, including FBXO7 (associated with PARK15), ATP13A2 (associated with Kufor-Rakeb syndrome/PARK9), and others. Many cases follow autosomal recessive inheritance, particularly those with juvenile or early-adult onset. Clinical presentation can vary depending on the underlying genetic cause but typically includes progressive parkinsonism that may be poorly responsive to levodopa, along with pyramidal signs. Additional features may include cognitive decline, dystonia, supranuclear gaze palsy, and psychiatric symptoms in some genetic subtypes. There is currently no cure for parkinsonian-pyramidal syndrome. Treatment is largely symptomatic and supportive. Levodopa therapy may provide partial or temporary benefit in some patients, though the response is often suboptimal compared to idiopathic Parkinson disease. Physical therapy, occupational therapy, and speech therapy play important roles in managing functional decline. Genetic counseling is recommended for affected families, and molecular genetic testing can help confirm the diagnosis and inform recurrence risk assessment.

Common questions about Parkinsonian-pyramidal syndrome